Teo, Min Yuen http://orcid.org/0000-0003-2511-6731
Al-Ahmadie, Hikmat http://orcid.org/0000-0002-2938-6627
Seier, Kenneth
Tully, Christopher
Regazzi, Ashley M.
Pietzak, Eugene
Solit, David B. http://orcid.org/0000-0002-6614-802X
Tickoo, Satish
Reuter, Victor
Cha, Eugene K.
Herr, Harry
Donahue, Timothy
Donat, Sherri M.
Dalbagni, Guido
Bochner, Bernard H.
Funt, Samuel http://orcid.org/0000-0002-7235-6319
Iyer, Gopakumar V.
Bajorin, Dean F.
Ostrovnaya, Irina
Rosenberg, Jonathan E.
Article History
Received: 19 August 2020
Revised: 15 December 2020
Accepted: 17 December 2020
First Online: 21 January 2021
Change Date: 10 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-022-01721-w
Ethics approval and consent to participate
: This study was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (#17–214). The need for informed consent was waived by the institutional review board. This study was performed in accordance with the Declaration of Helsinki.
: Anonymised data will be provided upon request.
: MYT has received Research Support from Bristol Myers Squibb, Clovis and Pharmacyclics; DBS has consulted with/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, BridgeBio, Vividion Therapeutics, Scorpion Therapeutics and Illumina; SAF has received research support from AstraZeneca, Genentech/Roche, is a consultant/advisory board member for Merck, and owns stock in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, and Inconovir; DFB has received research funding from Novartis, has received personal fees from Merck Sharp & Dohme, Eisai, Fidia Farmaceutici S.p.A., Lilly, and UroGen Pharma; and has received grants and personal fees from Bristol‐Myers Squibb, Roche/Genentech, and Novartis; and grants from Dendreon; GVI has received personal fees from Mirati Therapeutics and Janssen and research support from Novartis; JER has consulted for AstraZeneca, Bayer, Merck, BMS, Roche, Genentech, Seattle Genetics, Astellas, Boehringher Ingelheim, GSK, Mirati, Janssen, Lilly, and Pfizer. He has also received funding for clinical trials from Roche/Genentech, AstraZeneca, Bayer, Seattle Genetics and Astellas.
: This work was supported in part by the National Cancer Institute at the National Institutes of Health [P30 CA008748 to Memorial Sloan Kettering Cancer Center].